Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Announcement from Joincare Pharmaceutical Group Industry Co., Ltd. regarding winning the China Patent Excellence Award

Published Time:

2019-01-02

Stock Code: 600380 Stock Name: Health Yuan Announcement No.: 2018-129

 

          

 

Joincare Pharmaceutical Group Industry Co., Ltd.

 

Announcement on Winning the China Patent Gold Award

 

 

 

The board of directors and all directors of this company guarantee that the content of this announcement does not contain any false records, misleading statements or major omissions, and assume individual and joint liability for the authenticity, accuracy and completeness of its content.

 

 

 

Recently, the State Intellectual Property Office issued the "Decision on Awarding the 20th China Patent Award" (Guo Zhi Fa Yun Zi [2018] No. 36), and the invention patent of Shenzhen Tai Tai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "the Company"), "A Traditional Chinese Medicine Preparation for the Treatment of Women's Menopausal Syndrome" (Patent No.: ZL01139059.X) won the 20th China Patent Gold Award.

 

This award is an important award granted in accordance with the "Regulations on the Evaluation of China Patent Awards", recommended by relevant departments of the State Council's intellectual property management agencies, local intellectual property offices, relevant national industry associations, and Chinese Academy of Sciences and Chinese Academy of Engineering academicians, reviewed by the China Patent Award Review Committee, and audited and awarded by the State Intellectual Property Office and the World Intellectual Property Organization.

 

The award fully demonstrates the company's strength in independent research and development and technological innovation, representing the company's high level of technology and intellectual property protection awareness. The company will continue to increase R&D investment and continuously enhance the market competitiveness of its products.

 

 

 

This is hereby announced.